Key Highlights
- Evommune (NYSE:EVMN) was quoted 19.70% higher at USD 7.23 in premarket trading on November 5, 2026.
- Cash, cash equivalents and investments were USD 288.0 million at June 30, 2026, up from USD 216.7 million at December 31, 2025, with runway guided through 2028.
- The second-quarter 2026 net loss was USD 32.2 million, versus USD 13.6 million a year earlier, as Research and Development spending rose to USD 26.4 million.
- A Phase 2b trial of EVO756 in chronic spontaneous urticaria missed its primary endpoint at all doses in June 2026 and that indication was discontinued.
Latest Verified Update: Second-Quarter Report
Evommune (NYSE:EVMN) was quoted at USD 7.23, up 19.70%, in premarket trading on November 5, 2026, per the premarket quote. The most recent full financial update verified here is the second-quarter 2026 report, issued on August 6, 2026. The company held USD 288.0 million of cash, cash equivalents and investments at June 30, 2026, up from USD 216.7 million at December 31, 2025, and said its cash runway extends through 2028. The quarterly net loss was USD 32.2 million compared with USD 13.6 million a year earlier, while research and development expense was USD 26.4 million against USD 19.6 million and general and administrative expense was USD 8.5 million against USD 3.4 million. No Revenue was recorded in the 2026 periods.
Pipeline: Hits, a Miss and Upcoming Readouts
The pipeline is centred on EVO756, an oral drug for immune-driven skin and neurological conditions. In June 2026 its Phase 2b chronic spontaneous urticaria study missed its primary endpoint at all doses, and the company discontinued development in that condition. A Phase 2b atopic dermatitis trial of 120 patients with moderate-to-severe disease, measuring the relative change in the EASI skin score at Week 12, was guided for September 2026; the company's news listing shows a September 2026 top-line announcement, though its figures are not verified here. A Phase 2b migraine prevention trial of about 330 patients began in July 2026, with top-line data expected in 2027. A second candidate, EVO301, completed a Phase 2a atopic dermatitis study, and a Phase 2b is planned for mid-2027 with at least three subcutaneous dosing regimens. Chief Executive Luis Peña stressed a strong Balance Sheet to deliver multiple readouts.
Risks and What to Watch Next
Clinical-stage biotechs trade on binary outcomes. The urticaria miss shows a drug can Fail in one indication while working in another, and each future readout can move the stock sharply in either direction. Spending is climbing, with the six-month net loss at USD 53.9 million versus USD 28.1 million, so the USD 288.0 million of cash is the cushion that funds late-stage work. A premarket gain of 19.70% is a quote, not a close, and may reverse once regular trading opens. Investors should watch the migraine trial's progress, the full EVO301 dataset presentations, the planned Phase 2b start in mid-2027 and the third-quarter report, whose date and figures were not available at the time of writing.
Where Things Stand
The 19.70% premarket gain at Evommune (NYSE:EVMN) most plausibly reflects the market pricing a pipeline with several readouts ahead, supported by USD 288.0 million of cash and a runway through 2028. The evidence is balanced: the atopic dermatitis and migraine programs continue, but the urticaria failure and a widening loss of USD 32.2 million in the second quarter are real cautions. The move is a premarket quote on November 5, 2026 and can reverse. The next markers are the migraine data in 2027 and the EVO301 Phase 2b start.






Please wait processing your request...